Cohero Health and H&T Presspart have announced the availability of a new connected metered dose inhaler (eMDI). The eMDI collects actuation data from an integral sensor and transmits the data via Bluetooth to Cohero Health’s tracking platform. According to the companies, the system is compatible with all canisters and valves.
H&T Presspart Chairman Peter Schmelzer commented, “This partnership combines the strengths of two industry leaders. We saw a great opportunity to combine Cohero Health’s digital innovation with H&T Presspart’s expertise in MDI design and manufacturing. Together, we have developed an industry-leading offering. In addition to having a functional product, our capabilities as a manufacturer enable us to fully commercialize and supply this offering globally.”
Cohero Health CEO Melissa Manice said, “We’re excited to announce the addition of the eMDI to the Cohero Health portfolio. Our company’s mission is to transform respiratory care through smart mobile devices. Early in our product development, we recognized the importance of including tracking and communication capabilities into the MDI. Our eMDI is the natural evolution of Connected MDI our external medication sensors (HeroTrackers), and represents an exciting opportunity to better monitor adherence and quality of medication delivery, ultimately enabling improved medication use and prevention of avoidable exacerbations.”
Cohero Health Co-Founder and COO Daniel Weinstein added, “This announcement further demonstrates our commitment to leading innovation in respiratory care. The eMDI represents an exciting new tool for pharmaceutical companies to improve their product utilization, as well as enable unprecedented real-time monitoring of who is using their products, how they are using them, and how they are responding.”
Read the H&T Presspart press release.
